The settlement of the lawsuit may remove some immediate legal uncertainty for GSK, potentially stabilizing its stock in the short term. However, since GSK does not admit any liability and will continue to defend itself in other Zantac cases, the overall impact on the stock price is likely to be neutral. The ongoing legal battles may still pose a risk, but the resolution of this case removes one element of uncertainty.